NanoString announced Wednesday that it will be acquired by Bruker, ending the company's restructuring process that included a Chapter 11 bankruptcy plan.
SEATTLE--(BUSINESS WIRE)-- #AACR24--NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024. NanoString and its customers will showcase 110 posters and highlight its products.
Life science applications specialist NanoString (NASDAQ: NSTG ), which provides tools for discovery and translation research, announced that it has entered into a credit agreement with its existing lenders. Driving the need for such an arrangement was a bankruptcy filing at the beginning of the week.
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loa.
Investors looking at today's price action in NanoString (NASDAQ: NSTG ) stock ought to be shaking their heads in amazement. Indeed, after announcing the company would be filing for bankruptcy protection on Monday, many thought the story with NanoString was over.
NanoString Technologies (NASDAQ: NSTG ) stock is taking a beating on Monday after the company announced a voluntary Chapter 11 bankruptcy filing. NanoString Technologies notes that this bankruptcy filing is the result of its lost litigation battles against 10x Genomics.
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG) (“NanoString” or “the Company”), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to “Map the Universe of Biology.” With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy.
SEATTLE--(BUSINESS WIRE)-- #AGBT2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), Nan.
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager (SMI). The data will be highlighted at the 42nd annual J.P. Morgan Healthcare Conference 2024 in San Francisco during NanoString's corporate presentation on Wednesday, January 10, 20.
Seattle-based publicly traded biotech company NanoString Technologies said in a filing Friday that it plans to cut about 50 positions, or 9% of its workforce.
